M. HRTÁNKOVÁ1, K. BIRINGER1, K. LADIVEROVÁ1, P. KASAJOVÁ1, Z. LAUČEKOVÁ1, A. GONDOVÁ1, J. SOKOL2, J. DANKO1
The main use of low molecular weight heparins in an antepartum, peripartum
and postpartum period is the prophylaxis and treatment of venous thromboembolism,
which still represents a significant proportion of maternal morbidity and mortality.
The present paper offers an overview of the latest knowledge and the recommended
practices in the management of prevention of fatal pulmonary embolism.
Moreover, it deals with the use of low molecular weight heparins in pregnant women
with prosthetic heart valves and in women with recurrent miscarriage.